C-STRAND: COVID-19 Self-Testing Through Rapid Network Distribution

Sponsor
University of Pennsylvania (Other)
Overall Status
Recruiting
CT.gov ID
NCT04797858
Collaborator
Public Health Management Corporation (Other)
1,048
1
2
22.8
45.9

Study Details

Study Description

Brief Summary

COVID-19, the coronavirus disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has led to a global pandemic and has exacerbated existing health inequities among vulnerable populations. Despite higher rates of COVID-19 in Black and Latinx individuals compared to White individuals, rates of testing in predominately non-White, low-income communities are significantly lower than in high-income areas. Self-testing, where individuals collect their own samples, is now feasible for the detection of SARS-CoV-2. One promising approach to increase test uptake is the secondary distribution of self-testing kits, where an individual distributes tests to contacts in their social network and encourages them to self-test.

The central hypothesis of this clinical trial is that the secondary distribution of SARS-CoV-2 self-tests can significantly expand test uptake among underserved populations. To test this hypothesis, the investigators will conduct a 1:1 randomized controlled trial that will assess a self-testing intervention that promotes the secondary distribution of SARS-CoV-2 test kits compared with test referrals, with a focus on reaching underserved populations.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: COVID-19 self-test
  • Behavioral: COVID-19 test referral
N/A

Detailed Description

Strategies to rapidly disseminate COVID-19 testing are urgently needed, particularly to address increasing health disparities among underserved communities. One promising approach to increase test uptake is the secondary distribution of self-tests, where an individual distributes test kits to contacts in their social network and encourages them to self-test. By decentralizing testing, this approach does not require individuals to have contact with medical systems, and can lower potential barriers to obtaining testing. This approach can increase case detection by facilitating testing among exposed individuals, and potentially ameliorate stigma, fear, and medical mistrust associated with COVID-19 among vulnerable populations because the testing process is decentralized.

The investigators will conduct a 1:1 randomized controlled trial randomizing individuals to receive either multiple self-test kits to distribute within their social circles, or referrals for standard clinic-based tests. All study participants will be offered testing upon enrollment. Study participants, deemed "Index Participants," will be randomized to receive multiple self-testing kits (intervention) or test referral cards and text messages (control) to encourage individuals in their social networks, deemed "network contacts" to test. Participants will complete a baseline evaluation and a follow-up evaluation at 8 weeks. We will measure network contact test uptake in both study arms. The central hypothesis of this trial is that distribution of self-test kits will increase test uptake compared with distribution of test referrals.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1048 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Health Services Research
Official Title:
Secondary Distribution of COVID-19 Self-tests vs. Referrals to Increase Test Uptake in Underserved Populations
Actual Study Start Date :
May 5, 2021
Anticipated Primary Completion Date :
Jan 30, 2023
Anticipated Study Completion Date :
Mar 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Self-Test kit distribution

Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.

Behavioral: COVID-19 self-test
5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19. Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.

Active Comparator: Test referral distribution

Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.

Behavioral: COVID-19 test referral
5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19. These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites. Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.

Outcome Measures

Primary Outcome Measures

  1. Network contact test uptake [8 weeks]

    The primary outcome is the proportion of study participants who distributed tests/referrals to least two network contacts who completed testing. This outcome will be measured by the number of unique network contacts who completed a test linked to a study participant by week 8. The investigators will test for differences in the primary outcome between the two study arms.

Secondary Outcome Measures

  1. Network contact test uptake, end of study [Through study completion, up to one year]

    Test uptake among at least two network contacts. This outcome will be measured by the number of unique network contacts who completed a test linked to an index participant by end of study

  2. Number of contacts tested at 8 weeks [8 weeks]

    Number of unique network contacts who completed a test linked to an index participant by week 8.

  3. Number of contacts tested [Through study completion, up to one year]

    Number of unique network contacts who completed a test linked to an index participant by week 8.

  4. Number of positive contacts at 8 weeks [8 weeks]

    Number of network contacts who test positive

  5. Number of positive contacts [Through study completion, up to one year]

    Number of network contacts who test positive

  6. Test positivity rate per index participant [8 weeks]

    Proportion of Index Participant's network contacts who tested positive

  7. Proportion of first-time test takers [Through study completion, up to one year]

    Proportion of Index Participant's network contacts who self-report their test as their first COVID-19 test.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years of age or older

  • Has a working telephone number

  • Willing and able to provide informed consent

Exclusion Criteria:
  • Younger than 18 years of age

  • Does not have a working telephone number

  • Prior COVID-19 infection in the past 90 days

  • Previously received a COVID-19 test as part of this COVID-19 research study

  • Unable or unwilling to provide informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Public Health Management Corporation Philadelphia Pennsylvania United States 19102

Sponsors and Collaborators

  • University of Pennsylvania
  • Public Health Management Corporation

Investigators

  • Principal Investigator: Robert Gross, MD, University of Pennsylvania

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Robert Gross, Professor of Medicine, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT04797858
Other Study ID Numbers:
  • 3R01HL151292-01S1
First Posted:
Mar 15, 2021
Last Update Posted:
May 18, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2022